FindTrial
Sign In

Biomarkers for Metformin and Myo-inositol Drug Response in Polycystic Ovarian Syndrome

Pharmacoepigenomics Regulation by miRNAs in Myo-inositol and Metformin Drug Response Genes in the Polycystic Ovarian Syndrome - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/08/071982
Enrollment
252
Registered
2024-08-06
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome

Interventions

Intervention1: Metformin: Metformin is a biguanide antihyperglycemic used in conjunction with diet and exercise for glycemic control and insulin resistance in type 2 diabetes mellitus and polycystic o

Sponsors

Manipal Academy of Higher Education
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Females in the age group of 18-30 years 2. Those who have attained menarche 3. Patients diagnosed with PCOS as per Rotterdam diagnostic criteria (2003)

Exclusion criteria

Exclusion criteria: 1. Females in the age group of below 18 years and above 30 years of age 2. Those who have not attained menarche 3. Patients diagnosed with any chronic illness except Diabetes mellitus

Design outcomes

Primary

MeasureTime frame
HOMA IR (Homeostatic Model Assessment for Insulin Resistance) and ultrasound scanningTimepoint: Before the onset of drug treatment—

Secondary

MeasureTime frame
HOMA IR level is recheckedTimepoint: After 3 months of drug treatment—

Countries

India

Contacts

Public ContactDr Padmalatha S Rai

Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal

suprajamkodanch@gmail.com8553219217

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026